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Purpose: Infliximab is currently used for the treatment of active Crohn’s disease (CD). We aimed to assess the efficacy and safety 
of infliximab therapy and to determine the predictors of response in Korean patients with CD.
Materials and Methods: A total of 317 patients who received at least one infliximab infusion for active luminal CD (n=198) and 
fistulizing CD (n=86) or both (n=33) were reviewed retrospectively in 29 Korean referral centers. Clinical outcomes of induction 
and maintenance therapy with infliximab, predictors of response, and adverse events were evaluated.
Results: In patients with luminal CD, the rates of clinical response and remission at week 14 were 89.2% and 60.0%, respectively. 
Male gender and isolated colonic disease were associated with higher remission rates at week 14. In week-14 responders, the 
probabilities of sustained response and remission were 96.2% and 93.3% at week 30 and 88.0% and 77.0% at week 54, respectively. 
In patients with fistulizing CD, clinical response and remission were observed in 85.0% and 56.2% of patients, respectively, at 
week 14. In week-14 responders, the probabilities of sustained response and remission were 94.0% and 97.1%, respectively, at 
both week 30 and week 54. Thirty-nine patients (12.3%) experienced adverse events related to infliximab. Serious adverse events 
developed in 19 (6.0%) patients including seven cases of active pulmonary tuberculosis.
Conclusion: Infliximab induction and maintenance therapy are effective and well tolerable in Korean patients with luminal and 
fistulizing CD. However, clinicians must be aware of the risk of rare yet critical adverse events.
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INTRODUCTION
Crohn’s disease (CD) is a chronic disorder that causes inflam-
mation in any location of the gastrointestinal (GI) tract, although 
it is most commonly in the end of the small bowel and proximal 
large bowel.1,2 Patients with CD suffer from GI symptoms, such 
as abdominal pain and diarrhea, as well as disease-related 
complications, including stricture and fistula.1,2 Fistulas are 
common manifestations in CD due to its transmural nature. A 
variety of proteases and matrix metalloproteinases are released 
by immune activation, and these enzymes provoke tissue de-
struction, sinus tract formation, and ultimately penetration into 
adjacent tissues.3
Conventional medical therapies, such as 5-aminosalicylates, 
corticosteroids, and immunomodulators (IMMs) are effective 
in patients with CD; however, many patients continue to suffer 
from disabling conditions due to insufficient responses or side 
effects of these drugs.4-6 The introduction of infliximab, an anti-
body against tumor necrosis factor (TNF)-α, has greatly im-
proved treatment efficacy in patients with CD. Infliximab is a 
chimeric immunoglobulin G 1 monoclonal antibody that neu-
tralizes the biologic activity of TNF-α, which plays a central role 
in the pathogenesis of CD.7,8 In many studies, infliximab was ef-
fective in the induction and maintenance therapy of moderate 
to severely active CD in patients who had not responded to treat-
ments with a corticosteroid or IMMs. In addition, infliximab 
has been demonstrated to effectively induce and maintain a 
clinical response in patients with fistulizing CD and to induce 
mucosal healing in patients with active luminal CD.1,9,10 Treat-
ment with infliximab is generally well tolerated. However, inf-
liximab infusions can be associated with several adverse events, 
such as acute and delayed hypersensitivity (serum sickness-like 
reactions), infusion reactions, infectious complications, and 
hepatosplenic T-cell lymphomas.11,12
To date, most studies that have evaluated the efficacy and 
safety of infliximab have been conducted in patients in Western 
countries who have different genetic, ethnic, and environmen-
tal backgrounds from Asian patients.13 There are limited data 
regarding the efficacy and safety of infliximab for Asian CD pa-
tients. Moreover, many of the Western studies were random-
ized controlled trials (RCTs) that might not have properly inves-
tigated CD patients encountered during routine clinical practice. 
In fact, many patients with CD evaluated in an outpatient clinic 
may not qualify for enrollment in an RCT of biological reagents.14 
Use of infliximab is rapidly increasing with the accompanying 
increasing incidence of CD in Korea, and there is a specific con-
cern about reactivation of tuberculosis (TB), as the prevalence 
of latent and active TB remains high.15,16 Therefore, we aimed to 
investigate the efficacy and safety of infliximab therapy in Kore-
an patients with luminal and/or fistulizing CD and to identify 
clinical predictors of response to the therapy.
MATERIALS AND METHODS
Patients
This nationwide multicenter study was carried out at 29 referral 
hospitals in South Korea. We retrospectively reviewed the med-
ical records of CD patients with refractory luminal and/or fistu-
lizing disease who received at least one infliximab (Remicade®) 
infusion from 2002 to 2011. At each site, one member of the Ko-
rean Association for the Study of Intestinal Diseases was re-
sponsible for data collection.
Diagnosis of CD was based on standard clinical, radiologic, 
endoscopic, and histopathologic criteria which in turn were 
based on the Lennard-Jones criteria.17 Infliximab therapy was 
indicated for the treatment of moderate-to-severe luminal and/
or fistulizing CD in patients who had not responded to amino-
salicylates, corticosteroids, or IMMs.1,9 All patients received 5 
mg/kg infliximab intravenously at weeks 0, 2, and 6 for induc-
tion therapy and then every 8 weeks for maintenance therapy if 
the patients’ symptoms improved with induction therapy. If the 
response to maintenance therapy using infliximab had been 
inadequate, the dose was increased to 10 mg/kg. 
For all eligible patients, we collected demographic data, base-
line characteristics, previous and concomitant treatments, indi-
cation for infliximab, dose and number of infusions, clinical 
outcomes, and adverse events of infliximab treatment, particu-
larly those associated with TB. We used the definitions of ste-
roid dependency, steroid refractoriness, and immunomodula-
tor refractoriness described by the European Crohn’s and 
Colitis Organization consensus.2 The study protocol was ap-
proved by the Institutional Review Boards at all participating 
sites.
Outcome measures
For the evaluation of disease activity and the response to inflix-
imab therapy, Crohn’s Disease Activity Index (CDAI) values 
were collected at 0, 2, 6, 14, 30, and 54 weeks and at the last fol-
low-up visit after the first infusion of infliximab for luminal CD, 
and the status of fistula was determined at 0, 14, 30, and 54 
weeks and at the last follow-up visit for fistulizing CD.
Definitions of clinical response and remission were adopted 
from the ACCENT-I and II trials.18,19 In luminal CD, clinical re-
sponse to treatment was defined as a decrease in CDAI score of 
70 points or more from the baseline value and at least a 25% re-
duction in the total CDAI score, and complete response (remis-
sion) was defined as a CDAI score of less than 150. In fistulizing 
CD, clinical response to treatment was defined as a decrease of 
50% or more in the number of fistulas and draining discharge, 
and complete response (remission) was defined as a complete 
closure of fistulas on physical examination and/or imaging 
studies. An external fistula was considered to be closed if no dis-
charge was drained despite gentle finger compression. Patients 
with partial response were defined as those who had clinical 
response but did not achieve remission. Initial response and 
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remission rates were evaluated at 2, 6, and 14 weeks for luminal 
CD and at 14 weeks for fistulizing CD. The estimated rates of 
sustained clinical response and remission were determined at 
weeks 30 and 54 among patients who had clinical response or 
remission at week 14. Loss of response or remission was de-
fined by a CDAI score or fistula status that did not meet the re-
sponse or remission criteria at weeks 30 and 54.
Factors that might affect clinical remission at week 14 and 
sustained clinical remission at weeks 30 and 54 were evaluated 
as follows: sex, age at diagnosis, age at first infusion of inflix-
imab, time from diagnosis to first infusion, body mass index, 
smoking, disease location, concomitant medications, and labo-
ratory and colonoscopic findings.
Mucosal healing was defined as the absence of mucosal ul-
ceration in all segments examined via ileocolonoscopy. Serious 
adverse events were defined as those that were life threatening, 
required hospitalization, or led to significant disability or inca-
pacity.20
Statistical analysis
All continuous data are expressed as mean±standard deviation. 
We used Student’s t-test for continuous variables and the chi-
square test for discrete variables. Univariate and multivariate 
logistic regression analyses were used to identify predictors of 
complete response at week 14. A Kaplan-Meier analysis was 
used to estimate sustained response and remission rates at 
weeks 30 and 54, and a log-rank test was used to identify pre-
dictors associated with sustained clinical remission. Patients 
with sustained clinical response or remission were censored at 
the last clinical visit. All p values were two-tailed, and p values 
of <0.05 were considered to be statistically significant. Statistical 
analyses were performed using SPSS version 18.0 for Windows 
(SPSS, Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics 
A total of 317 CD patients were included in this study, and data 
were collected from September 2009 through September 2011. 
All of the patients received at least one infliximab infusion for 
the treatment of CD between 2002 and 2011, with a mean fol-
low-up of 23.2±18.8 months from the first infusion. Mean ages 
at diagnosis and at first treatment with infliximab for CD were 
25.9±10.2 (range 12–79) and 29.5±10.8 (range 14–79) years, re-
spectively. Regarding past medical history, 17 patients had a 
history of active TB. A tuberculosis skin test (TST), interferon 
gamma releasing assay (IGRA), or both tests were performed in 
Table 1. Baseline Characteristics of the Patients
Characteristics n=317 (%)
Sex, male:female 206 (65.0%):111 (35.0%)
Age, mean±SD
Age at diagnosis 25.9±10.2
Age at 1st infliximab treatment 29.5±10.8
Body mass index (kg/m2) 19.1±3.2
Family history of IBD 6 (1.9%)
Disease duration prior to infliximab (yrs), mean±SD 4.1±4.2
Disease type
Active luminal disease 198 (62.5%)
Fistulizing disease 86 (27.1%)
Both 33 (10.4%)
Fistula location in fistulizing CD
Perianal 81 (68.1%)
Enterocutaneous 35 (29.4%)
Entero-enteric 8 (6.7%)
Enterovesical 5 (4.2%)
Rectovaginal 6 (5.0%)
Disease location 
Small bowel 50 (15.8%)
Colon 60 (19.0%)
Both 207 (65.3%)
CDAI, mean±SD 279.3±92.0
Laboratory findings
Hemoglobin (g/dL), mean±SD 11.3±1.9 
C-reactive protein (mg/dL), mean±SD 6.9±19.5
Albumin (g/dL), mean±SD 3.6±1.6
Previous medication
5-ASA 280 (88.3%)
Antibiotics 185 (58.4%)
Corticosteroid 217 (68.5%)
AZA or 6-MP 243 (76.7%)
Methotrexate 6 (1.9%)
Concomitant medication
5-ASA 247 (77.9%)
Antibiotics 100 (31.5%)
Corticosteroid 94 (29.7%)
AZA or 6-MP 185 (58.4%)
Methotrexate 0 (0%)
Previous segmental resection 166 (52.4%)
Smoking habit
Nonsmokers 257 (81.1%)
Former smokers 25 (7.9%)
Current smokers 18 (5.7%)
Unknown 17 (5.4%)
Table 1. Baseline Characteristics of the Patients (Continued)
Characteristics n=317 (%)
Tuberculosis history 17 (5.4%)
Chronic hepatitis
CHB/HBV carrier 8 (2.5%)
CHC 2 (0.6%)
IBD, inflammatory bowel disease; CD, Crohn’s disease; CDAI, Crohn’s disease 
activity index; CRP, C-reactive protein; 5-ASA, 5-aminosalicylates; AZA, aza-
thioprine; 6-MP, 6-mercaptopurine; CHB, chronic hepatitis B; HBV, hepatitis B 
virus; CHC, chronic hepatitis C.
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183 (57.7%), 100 (31.5%), and 56 (17.7%) patients, respectively, 
for latent TB infection (LTBI), and positive findings of TST, 
IGRA, and both tests were observed in 18 (9.8%), 11 (11%), and 
one (1.8%) patient, respectively. A simple chest X-ray was per-
formed in all patients before infliximab infusion, and five pa-
tients had TB scar changes. Patients who had at least one posi-
tive finding among TB scars on chest X-ray, TST, and IGRA were 
considered to have LTBI (n=33). Among these 33 patients, 18 
patients had received TB prophylaxis. Six patients had a family 
history of inflammatory bowel disease (CD: 5; ulcerative colitis: 
1). In colonoscopic findings, ileocolonic ulcers (excluding aph-
thous ulcers) were observed in 79.7% (192 of 241), and a cobble-
stone appearance was observed in 37.3% (90 of 241). The base-
line characteristics of the patients are summarized in Table 1.
Infliximab therapy
The indication of infliximab therapy was as follows: 198 patients 
(62.5%) were treated for active luminal CD, 86 patients (27.1%) 
for fistulizing CD, and 33 patients (10.4%) for both active lumi-
nal and fistulizing CD. Among the patients with active luminal 
CD, 56 (28.3%) had steroid dependency, 30 (15.2%) had steroid 
refractoriness, and 98 (49.5%) had IMM refractoriness. Among 
119 patients with fistulas, 99 (83.2%) had external fistulas, and 
28 (23.5%) had internal fistulas. The median number of inflix-
imab infusions was eight, ranging from one to 31. The standard 
dose of 5 mg/kg infliximab was administered and maintained 
in most cases. During infliximab therapy, a dose increase was 
applied in eight patients (2.5%) and an interval decrease in two 
(0.6%). One hundred thirty-three (42%) patients discontinued 
therapy due to primary non-response (n=26), loss of response 
(n=23), intolerable adverse events (n=12), follow-up loss 
(n=16), economic difficulties (n=12), disease remission (n=27), 
or other reasons (n=17). A flow chart of the study population for 
each analysis is presented in Fig. 1.
Efficacy of infliximab in active luminal CD
After the first infusion of infliximab, treatment efficacy was as-
sessed in 227 patients at week 2, 206 patients at week 6, and 185 
patients at week 14 among the 231 patients who were diag-
nosed with luminal CD or both luminal and fistulizing CD. Clini-
Fig. 2. Clinical response (complete and partial response) and remission 
(complete response) at weeks 2, 6, and 14 in patients with active luminal 
Crohn’s disease.
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cal response and remission were observed in 163 (71.8%) and 
89 (39.2%) patients at week 2, in 177 (85.9%) and 110 (53.4%) at 
week 6, and in 165 (89.2%) and 111 (60.0%) at week 14, respec-
tively (Fig. 2). CDAI scores at weeks 2, 6, and 14 decreased from 
the baseline value of 295.0±82.9 to 150.3±72.0, 132.1±70.2, and 
134.1±84.1 at each time point, respectively. An analysis to iden-
tify factors related to clinical remission at week 2 showed a sig-
nificantly higher likelihood of remission in patients whose first 
infusion of infliximab was less than 3 years from diagnosis than 
in those whose first infusion was greater than 3 years (47.1% vs. 
30.6%, p=0.011); however, no other factors were associated with 
the remission rate. There was no factor associated with the re-
mission rate at week 6. On analysis of the factors related to clini-
cal remission at week 14, male gender and isolated colonic dis-
ease were associated with a high remission rate (Table 2). On 
multivariate logistic regression analysis, male gender [odds ra-
tio (OR)=1.99, 95% confidence interval (CI): 1.06–3.73, p=0.032] 
and isolated colonic disease (OR=4.96 vs. small bowel disease, 
95% CI: 1.68–14.67, p=0.004) were significantly associated with 
the remission rate. The other factors were not associated with 
the remission rate at week 14.
Among 165 patients who had a partial or complete response 
at week 14, the estimated rates of sustained clinical response 
were 96.2% at week 30 and 88.0% at week 54, respectively, on 
Kaplan-Meier analysis. In 111 patients with complete response 
(remission) at week 14, the estimated rates of sustained clinical 
remission were 93.3% at week 30 and 77.0% at week 54, respec-
tively (Fig. 3). Log-rank test results showed that no clinical fac-
tors were associated with the remission rate at week 30 as well 
as at week 54, including sex, time from diagnosis to first infu-
sion of infliximab, and concomitant IMM use.
Of 231 patients, 170 received ileocolonoscopy before inflix-
imab therapy. Active ulcerations and a cobblestone appearance 
were found in 141 (82.9%) and 65 (38.2%) patients, respectively. 
Among 54 patients who underwent follow-up ileocolonoscopy, 
mucosal healing was present in 32 (59.3%). The mean interval 
between the initial and follow-up ileocolonoscopies was 
33.7±28.9 (range 2–121 months). There were no clinical factors 
associated with the mucosal healing rate.
To evaluate the long-term efficacy, we performed a sub-
analysis in the 185 patients who were followed-up for 6 months 
or more. The mean follow-up period was 28.3±18.4 months 
(range 6–103 months). At the time of the last follow-up, the 
mean CDAI score was 122.3±84.4 (range 10.6–475). Of the 185 
patients, 111 (60.0%) were in remission, 54 (29.2%) had mild 
disease, and 20 (10.8%) had moderate or severe disease based 
on CDAI scores. The remission rate was higher in patients with 
mucosal healing than in those without mucosal healing on the 
follow-up ileocolonoscopies (78.1% vs. 50.0%, p=0.031).
Efficacy of infliximab in fistulizing CD
Among the 119 patients who were diagnosed with fistulizing 
CD or both luminal and fistulizing CD, the efficacy of induction 
therapy was assessed at week 14 in 73 patients who received 
three doses of infliximab. Clinical response and remission were 
observed in 62 (85.0%) and 41 patients (56.2%), respectively (Fig. 
4). The clinical response and remission rates tended to be high-
er in patients with external fistulas than in those with internal 
fistulas (87.3% and 58.2% for external fistulas vs. 69.2% and 
46.2% for internal fistulas, respectively), and among the patients 
with external fistulas, these rates tended to be higher in patients 
with perianal fistulas than in those with enterocutaneous fistu-
Table 2. Predictive Factors Related to Clinical Remission at Week 14 in 
Luminal Crohn’s Disease
Remission at 
week 14
p value
Sex 0.025
Male 78/118 (66.1%)
Female 33/67 (49.3%)
Age at diagnosis (yr) 0.760
≤25 65/110 (59.1%)
>25 46/75 (61.3%)
Age at 1st infliximab treatment (yr) 0.114
≤25 52/78 (66.7%)
>25 59/107 (55.1%)
Time from diagnosis to first infusion (yr) 0.401
≤3 years 58/92 (63%)
>3 years 53/93 (57%)
Body mass index (kg/m2) 0.640
≤20 70/118 (59.3%)
>20 39/62 (62.9%)
Smoking 0.544
Non-smoker 88/149 (59.2%)
Smoker 17/26 (65.4%)
Concomitant use of steroid 0.845
No 78/129 (60.5%)
Yes 33/56 (58.9%)
Concomitant use of AZA/6-MP 0.201
No 42/77 (54.5%)
Yes 69/108 (63.9%)
Hemoglobin (g/dL) 0.391
≤10 35/54 (64.8%)
>10 76/131 (58%)
C-reactive protein (mg/dL) 0.175
≤2 46/82 (56.1%)
>2 50/75 (66.7%)
Disease location 0.009
Small bowel 15/33 (45.5%)
Colon 29/36 (80.6%)
Both 67/116 (57.8%)
Ulcers in ileocolonoscopy at diagnosis 0.129
No 10/20 (50%)
Yes 79/117 (67.5%)
AZA, azathioprine; 6-MP, 6-mercaptopurine.
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las (89.6% and 56.3% for perianal fistulas vs. 77.8% and 66.7% 
for enterocutaneous fistulas, respectively) without statistical 
significance. No other clinical factors were associated with the 
remission rate at week 14 (Table 3).
Among the 62 patients who had a partial or complete re-
sponse at week 14, three failed to maintain sustained clinical 
response at weeks 30 and 54. In 41 patients with complete re-
sponse (remission) at week 14, one did not maintain sustained 
clinical remission at weeks 30 and 54. The estimated rates of 
sustained clinical response and remission were 94.0% and 
97.1%, respectively, at both weeks 30 and 54. The predictive fac-
tors for the sustained remission were not analyzed, as only one 
patient failed to sustain remission at weeks 30 and 54.
To evaluate the long-term efficacy, we performed a sub-
analysis in the 104 patients who were followed-up for 6 months 
or more. The mean follow-up period was 30.3±19.0 months 
(range 6–103 months). At the time of the last follow-up, the clini-
cal response and remission rates were 78.8% (82 of 104) and 
54.8% (57 of 104), respectively.
Adverse events
During the follow-up period, 34 patients (10.7%) had new CD-
related complications as follows: 27 strictures, three perianal 
fistulas, three intra-abdominal abscesses accompanying inter-
nal fistulas, and one case of intractable GI bleeding. Twenty-
seven patients (8.5%) underwent operations as follows: seven 
anal fistulectomies (or fistulotomies), four seton operations, 15 
segmental bowel resections, and one total proctocolectomy 
and ileostomy.
Overall, 39 patients (12.3%) experienced an adverse event 
during infliximab therapy (Table 4). All of the adverse events 
could be directly attributed to infliximab. Two of the eight pa-
tients who had chronic hepatitis B or were hepatitis B virus car-
riers experienced mild elevation of alanine aminotransferase, 
although these responses spontaneously improved. Eighteen 
patients (5.7%) discontinued infliximab due to serious adverse 
events: seven cases of severe infusion reactions, two cases of se-
rum sickness, two cases of intra-abdominal abscess, and seven 
cases of active tuberculosis. There were no mortalities in this 
study.
In terms of tuberculosis, seven cases of active pulmonary TB 
developed during infliximab therapy. Two of these patients had 
negative results in both latent TB screening tests (TST and 
IGRA), and three did not undergo either latent TB test. One pa-
tient had a past history of pulmonary TB and scar change on 
her chest X-ray and received anti-TB prophylaxis for 9 months 
with isoniazid (INH), with initiation of infliximab after 3 weeks 
of INH medication. In all seven patients, pulmonary TB was 
cured with anti-TB medications; however, infliximab treatment 
was restarted in only one patient who continued infliximab 
therapy for 28 months without TB reactivation. Detailed infor-
mation on patients with active TB is provided in Table 5.
DISCUSSION
This report presents a relatively large-scale Asian study on the 
efficacy and safety of infliximab therapy for CD. In patients with 
active luminal CD, clinical response and remission rates were 
89.2% and 60.0%, respectively, at week 14. The estimated rates 
of sustained clinical response and remission were 96.2% and 
93.3% at week 30 and 88.0% and 77.0% at week 54, respectively, 
among the week-14 responders. For fistulizing CD, clinical re-
sponse and remission rates were 85.0% and 56.2%, respectively, 
at week 14, and the clinical responses were maintained in most 
of the week-14 responders at both weeks 30 and 54. The initial 
responses of infliximab on fistulizing CD tended to be more ef-
fective in patients with external fistulas, more so in those with 
perianal fistulas than in those with internal fistulas.
The results for the response to induction therapy in our study 
are comparable to those of previous studies that used inflix-
imab, which reported early response rates of 58–96% and re-
Fig. 3. (A) Cumulative probabilities of sustained clinical response for week 14 responders and (B) cumulative probabilities of sustained clinical remission 
for patients in remission at week 14 among patients with active luminal Crohn’s disease. 
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mission rates of 40–73%.21-25 However, the sustained response 
and remission rates in patients with luminal CD were slightly 
higher than those of previous randomized, controlled trials 
(RCTs) such as the ACCENT-I study, in which the clinical re-
sponse and remission rates were 50% and 39% at week 30 and 
39% and 30% at week 54, respectively.18 Additionally, the esti-
mated response rates of maintenance treatments in patients 
with fistulizing CD in our study were higher than those in the 
ACCENT-II study in which the proportions of patients with re-
sponse and remission were 46% and 36% at week 54, respec-
tively.19 This disparity in response rates may be explained by 
differences in the characteristics of the patients (ethnicity, indi-
cations for infliximab, disease severity, and extension) or in the 
study design (RCT or not).
Current treatment goals for CD are changing from the induc-
tion of symptomatic remission to the achievement of mucosal 
healing, as the latter leads to improved long-term clinical out-
comes.26,27 Mounting evidence suggests that achieving mucosal 
healing may change the natural course of the disease by de-
creasing the need for surgery and reducing hospitalization rates 
of CD patients.28 Mucosal healing is now recognized as a new 
therapeutic goal in CD, at least in clinical trials.29 Consistent 
with this approach, mucosal healing was associated with a 
higher long-term remission rate in our study. However, this re-
sult must be validated in a future prospective study.
In the analysis of the factors related to clinical remission at 
week 2 for luminal CD, patients whose first infusion of inflix-
imab was less than 3 years from diagnosis had higher remission 
rates than those whose first infusion occurred more than 3 
years after diagnosis. This is compatible with previous reports 
that have convincingly shown that anti-TNF therapy is more ef-
Table 3. Predictive Factors Related to Clinical Remission at Week 14 in 
Fistulizing Crohn’s Disease
Remission 
at week 14
p value
Sex 0.370
Male 24/46 (52.2%)
Female 17/27 (63.0%)
Age at diagnosis (yr) 0.679
≤25 30/52 (57.7%)
>25 11/21 (52.4%)
Age at 1st infliximab treatment (yr) 0.918
≤25 21/37 (56.8%)
>25 20/36 (55.6%)
Time from diagnosis to first infusion (month) 0.448
≤3 22/42 (52.4%)
>3 19/31 (61.3%)
Body mass index (kg/m2) 0.736
≤20 28/48 (58.3%)
>20 13/24 (54.2%)
Smoking 0.918
Non-smoker 35/61 (57.4%)
Smoker 5/9 (55.6%)
Concomitant use of steroid 0.226
No 31/51 (60.8%)
Yes 10/22 (45.5%)
Concomitant use of AZA/6-MP 0.238
No 17/26 (65.4%)
Yes 24/47 (51.1%)
Concomitant use of antibiotics 0.526
No 21/35 (60.0%)
Yes 20/38 (52.6%)
Hemoglobin (g/dL) 0.891
≤10 10/18 (55.6%)
>10 31/54 (57.4%)
C-reactive protein (mg/dL) 0.980
≤2 21/39 (56.1%)
>2 13/24 (66.7%)
Type of fistula 0.984
Perianal fistula only 27/48 (56.3%)
Others 14/25 (56.0%)
AZA, azathioprine; 6-MP, 6-mercaptopurine.
Table 4. Adverse Events during Infliximab Therapy 
n=317 (%)
Total adverse events, n (%) 39 (12.3)
Infusion reaction 17 (5.4)
Serum sickness 9 (2.8)
Infection disease 11 (3.5)
Chronic hepatitis B aggravation 2/8 (25.0)
Chronic hepatitis C aggravation 0/2 (0)
Serious adverse events, n (%) 19 (6.0)
Severe infusion reactions 7 (2.2)
Serum sickness-like reactions 2 (0.6)
Serious infections 10 (3.2)
Fig. 4. Clinical response (complete and partial response) and remission 
(complete response) at week 14 in patients with fistulizing Crohn’s dis-
ease.
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fective in patients with a short disease history.30,31 However, the 
disease duration from diagnosis to first infusion of infliximab 
was not associated with clinical remission at weeks 6 and 14. In 
the analysis to identify factors affecting the remission rate at 
week 14, sex and disease location were significantly associated 
with the remission rate. However, the disease location was not 
associated with response rates at weeks 2 and 6. Thus, we can-
not confidently suggest the predictive factors for initial response 
to infliximab due to the inconsistency of the results. A future pro-
spective study may confirm the possibility of sex, disease loca-
tion, and duration as predictive factors for initial response to in-
fliximab in luminal CD.
No factors were associated with the efficacy of maintenance 
therapy in luminal CD, including sex, disease location, and du-
ration. The SONIC trial demonstrated that the combination of 
infliximab and azathioprine (AZA) was superior to either inflix-
imab or AZA alone in patients with active luminal CD naive to 
IMMs and biologics.32 A large portion of the patients in our 
study (76.7%) had experienced IMMs before infliximab thera-
py; therefore, the response rates did not appear to be different 
between the combination therapy of infliximab plus AZA and 
infliximab alone. In addition, patients with high baseline C-re-
active protein, those with isolated colonic disease and no previ-
ous abdominal surgery, young patients, and nonsmokers have 
all been suggested to be more likely to respond to anti-TNF 
therapy.9 However, these factors were not related to the mainte-
nance effect of infliximab therapy in our study. Only isolated 
colonic disease was associated with initial response. These dis-
crepancies might also originate from differences in the charac-
teristics and ethnicity of the study population or the study de-
sign (prospective or retrospective). Factors related to the efficacy 
of maintenance therapy using infliximab also need to be inves-
tigated more in a prospective study.
Induction and maintenance therapy with infliximab was well 
tolerated in Korean patients with CD. Overall, 39 patients (12.3%) 
experienced an adverse event during infliximab therapy. As 
this study was conducted retrospectively, the overall incidence 
of adverse events, including infusion reactions and infections 
(not serious) might have been lower than in the ACCENT-I and 
II trials. However, the reported incidence of serious adverse 
events was similar to those in previous studies.18,19 In this study, 
19 patients (6.0%) had serious adverse events, including seven 
cases of active pulmonary tuberculosis. Fortunately, there were 
no mortalities, and all cases of active TB were safely cured with 
anti-TB medications.
TB is significantly more common in South Korea than in oth-
er developed countries. In the USA, the incidence rate of TB 
was 3.2 per 100000 person-years in 2012 and is currently in de-
cline,33 whereas the incidence of TB in the general Korean pop-
ulation is 92 per 100000 person-years.34 Moreover, anti-TNF 
therapy was shown to be associated with a 2.5- to 18-fold in-
crease in the incidence of TB infection compared to healthy con-
trols, although the actual incidence was not particularly high.34-39 
Thus, screening tests to confirm active TB and LTBI prior to 
starting anti-TNF therapy are essential. According to the Korean 
guidelines for TB, patients who are to be treated with anti-TNF 
agents should first be checked regarding their past TB history, 
contact history with patients with TB, and present suspected 
symptoms of TB and should have a chest X-ray examination 
and TB infection tests.34,40 The TB infection tests should be per-
formed by using an IGRA alone or both an IGRA and a TST. A 
TST alone is not recommended for testing TB infection in pa-
tients with inflammatory bowel disease, as the use of immuno-
suppressive agents may lead to a false negative TST result due to 
anergy.34,40 In our study, the incidence of active TB was relatively 
high; moreover, two patients had negative results in TB infection 
tests (TST and IGRA) and normal chest X-ray results, and anoth-
er patient received anti-TB prophylaxis (INH, 9 months) due to 
LTBI among the seven patients in whom active TB developed. 
Thus, a screening test for TB infection using both a TST and an 
IGRA at one time before starting infliximab may not be suffi-
cient to prevent active TB development, particularly in countries 
with a high prevalence of TB. Physicians should thoroughly re-
view patient histories, TST and IGRA results, and chest X-ray 
findings before commencing anti-TNF therapy for CD, and they 
should also pay attention to the risk of TB development even if 
the patients do not have LTBI or have taken treatment for LTBI. 
In addition, a substantial portion of TB cases (71%, 5 of 7) oc-
curred within 3 months after infliximab initiation. Thus, more 
attention to TB development may be needed during the early 
period of infliximab therapy.
A limitation of our study was its retrospective design. More-
Table 5. Details of Tuberculosis Infection
No. Patient (age/sex) TB history TST* IGRA Chest PA (X-ray) Prophylaxis IMMs Steroid Interval to active TB (months)
1 26/M No (-) (-) NL ND Yes Yes 30
2 43/M No ND ND NL ND No Yes 3
3 62/M No ND ND NL ND No Yes 2
4 33/M No (-) (-) NL ND Yes No 12
5 43/M No ND (-) NL ND No No 2
6 32/M No ND ND NL ND Yes No 2
7 46/F Yes/lung (-) ND TB scar INH/9 months Yes No 2
TB, tuberculosis; TST, tuberculosis skin test; IGRA, interferon gamma releasing assay; IMM, immunomodulator; NL, normal; ND, not done; INH, isoniazid.
*A purified protein derivative reaction measuring less than 10 mm was considered negative in TST.
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over, we did not evaluate trough levels and antibodies to inflix-
imab. Nonetheless, this was a relatively large-scale, nationwide, 
multicenter study to evaluate the efficacy and safety in Korean 
patients with CD, and it provided baseline data for subsequent 
well-designed prospective studies.
In conclusion, we have demonstrated the efficacy of inflix-
imab in induction and maintenance treatments in Korean pa-
tients with luminal and fistulizing CD. Infliximab treatment was 
safe and well tolerated. However, physicians should always be 
cautious about the possible adverse effects of infliximab, par-
ticularly for TB. Further prospective studies are needed to eval-
uate the long-term efficacy and safety of infliximab therapy and 
to determine the predictors of response in patients with CD. 
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